Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience

In October 2002, the U.S. Food and Drug Administration approved buprenorphine-naloxone (Suboxone(®)) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for Clinical Trials Network (CTN) sponsored two clinic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Amass, Leslie, Ling, Walter, Freese, Thomas E., Reiber, Chris, Annon, Jeffrey J., Cohen, Allan J., M.F.T., McCarty, Dennis, Reid, Malcolm S., Brown, Lawrence S., Clark, Cynthia, Ziedonis, Douglas M., Krejci, Jonathan, Stine, Susan, Winhusen, Theresa, Brigham, Greg, Babcock, Dean, L.C.S.W., Muir, Joan A., Buchan, Betty J., Horton, Terry
Formato: Artigo
Idioma:Inglês
Publicado em: 2004
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1255908/
https://ncbi.nlm.nih.gov/pubmed/15204675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10550490490440807
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados